2026-06-14T04:01:35Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/199522024-07-03T11:01:15Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Martinez-Serra, Jordi
author
del Campo Garcia, Raquel
author
Gutierrez, Antonio
author
Antich, Jose Luis
author
Ginard, Magdalena
author
Duran Pastor, Maria Antonia
author
Bento, Leyre
author
Ros, Teresa
author
Amat, Juan C
author
Vidal, Carmen
author
Iglesias, Julio F
author
Orlinska, Izabela
author
Besalduch Vidal, Juan
2024-07-03T11:01:15Z
2024-07-03T11:01:15Z
2014
Martinez-Serra J, Del Campo R, Gutierrez A, Antich JL, Ginard M, Duran MA, et al. Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.. Biomark Res. 2014;2:14.
10.1186/2050-7771-2-14
2050-7771
Biomarker Research
http://hdl.handle.net/20.500.13003/17107
25197554
L603849551
2-s2.0-85006228432
http://hdl.handle.net/20.500.12105/19952
Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a hematopoietic stem cell. CML is cytogenetically characterized by the presence of the Philadelphia chromosome (Ph'). Most patients with CML express e13a2 or e14a2 mRNAs that result from a rearrangement of the major breakpoint cluster regions (M-BCR) generating the 210-kDa (p210BCR-ABL) fusion proteins b2a2 or b3a2 respectively. The e1a3 CML-related atypical translocation has been reported with an indolent clinical course, low leukocyte count, long chronic phase even without treatment and good response to therapy. We report the case of a patient initially diagnosed as CML in chronic phase whose cells expressed the e1a3 variant. The patient readily responded to imatinib 400mg with the achievement of a rapid complete cytogenetic response and the normalization of the blood count values, but after 5months transformed into lymphoid blast crisis.
eng
ALL
CML
bcr-abl
e1a3
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.
research article